Generate Biomedicines Inc’s (NASDAQ:GENB) Quiet Period Will End on April 8th

Generate Biomedicines’ (NASDAQ:GENB) quiet period will end on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its public offering on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective on the stock. Piper Sandler started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 target price for the company. Morgan Stanley initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating for the company. Finally, Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Generate Biomedicines Stock Performance

Shares of GENB opened at $12.50 on Wednesday. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.